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Background: The expression of 2′-5′-Oligoadenylate synthetases (OASs) is induced by type 1 Interferons (IFNs) in
response to viral infection. The OAS proteins have a unique ability to produce 2′-5′ Oligoadenylates, which bind
and activate the ribonuclease RNase L. The RNase L degrades cellular RNAs which in turn inhibits protein translation
and induces apoptosis. Several single nucleotide polymorphisms (SNPs) in the OAS1 gene have been associated
with disease. We have investigated the functional effect of two common SNPs in the OAS1 gene. The SNP
rs10774671 affects splicing to one of the exons in the OAS1 gene giving rise to differential expression of the OAS1
isoforms, and the SNP rs1131454 (former rs3741981) resides in exon 3 giving rise to OAS1 isoforms with either a
Glycine or a Serine at position 162 in the core OAS unit.
Results: We have used three human cell lines with different genotypes in the OAS1 SNP rs10774671, HeLa cells
with the AA genotype, HT1080 cells with AG, and Daudi cells with GG. The main OAS1 isoform expressed in Daudi
and HT1080 cells was p46, and the main OAS1 isoform expressed in HeLa cells was p42. In addition, low levels of
the OAS1 p52 mRNA was detected in HeLa cells and p48 mRNA in Daudi cells, and trace amounts of p44a mRNA
were detected in the three cell lines treated with type 1 interferon. We show that the OAS1 p46 isoform was
localized in the mitochondria in Daudi cells, whereas the OAS1 isoforms in HeLa cells were primarily localized in
cytoplasmic vacuoles/lysosomes. By using recombinantly expressed OAS1 mutant proteins, we found that the OAS1
SNP rs1131454 (former rs3741981) did not affect the enzymatic OAS1 activity.
Conclusions: The SNP rs10774671 determines differential expression of the OAS1 isoforms. In Daudi and HT1080
cells the p46 isoform is the most abundantly expressed isoform associated with the G allele, whereas in HeLa cells
the most abundantly expressed isoform is p42 associated with the A allele. The SNP rs1131454 (former rs3741981)
does not interfere with OAS1 enzyme activity. The OAS1 p46 isoform localizes to the mitochondria, therefore a full
2-5A system can now be found in the mitochondria.
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The interferon (IFN) system is activated in response to
viral infection and plays an important role in the host
defence system. Type I IFNs induce proteins with anti-
viral activity such as double-stranded RNA-activated
protein kinase (PKR), 2′,5′-Oligoadenylate synthetases* Correspondence: pmm@mb.au.dk
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unless otherwise stated.(OASs), RNase L, and the Mx protein GTPases [1,2]. Our
focus here is the OAS family of enzymes, which catalyses
the synthesis of oligoadenylates of the general structure
ppp(A2′p)nA, commonly abbreviated 2-5A. RNase L, a
latent endoribonuclease, becomes activated upon binding
of 2-5As, and when activated it catalyses the degradation
of both viral and cellular RNAs, including ribosomal RNA
[3]. This antiviral response results in inhibition of protein
synthesis and in some cases it causes apoptosis. Three
genes encoding enzymatic active OAS enzymes have beend. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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characterization of cDNA and genomic clones, and they
are designated OAS1, OAS2, and OAS3 [4,5]. The human
OAS1 gene encodes at least six isoforms with different
theoretical molecular weights, p42, p44a, p44b, p46, p48
and p52 (Figure 1A). The OAS1 isoforms are splice
variants and contain the same five core exons but differ in
their 3′ exons. The OAS1 isoforms p42 and p46, the









Figure 1 The human OAS1 splice variants and single nucelotide polym
position of known single nucleotide polymorphisms (SNPs) in the exons. A
boxes), but contain different 3′ exons resulting from alternative splicing (gr
B. The consequence of some of the OAS1 SNPs for the encoded proteins.splicing of the OAS2 gene, and the OAS3 isoform p100
have been detected at the protein level in human cells
[6,7], whereas the p52, p48, p44a and p44b OAS1 isoforms
have only been detected at the mRNA level in cells treated
with IFN [4,8-10].
It has previously been demonstrated that the cellular
localization of the OAS proteins differs. It has been
shown by electron microscopy that the human OAS2
















orphisms. A. Schematic view of the human OAS1 gene and the
ll mature OAS1 mRNAs share the same core unit, exon 1-5 (black
ey boxes). The p42 mRNA variant results from no splicing of exon 5.
The SNPs discussed in this paper are marked in bold.
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OAS3 p100 isoform is localized to the cytoplasm [12],
whereas the OAS1 p42 isoform was found mainly in the
cytoplasmic fraction and the p46 isoform mainly in the
microsomal fraction of cells [6].
The expression of the OAS1 isoforms are cell-type
specific [6,7,13], and the differential expression patterns
of some of the OAS1 isoforms can be related to a single-
nucleotide polymorphism (SNP) rs10774671 situated in
the splice acceptor site at the 5′ end of exon 7 in the
OAS1 gene (Figure 1) [9]. The two alleles have been
named A and G, since one has a splice acceptor site in
exon 7 with an AAG sequence, and the other has a
splice acceptor site with an AGG sequence. The AGG
splice acceptor site (G allele) results in mRNAs encoding
p46, and the AAG splice acceptor site results in an
mRNA encoding p52, since the splice site between exon
5 and exon 7 has shifted one nucleotide downstream.
The expression of p48 results from splicing 98 nucleo-
tides downstream from the exon 7 start site, and the
expression of p42 derives from mRNA linking exon 5
and exon 6 without splicing.
The rs10774671 SNP has been associated with two
autoimmune diseases, Type 1 diabetes and mutiple
sclerosis. In Type 1 diabetes, it was found that affected
persons were predominantly homozygous for the G allele
[14], and this association was confirmed by others [15].
These authors further concluded that the rs10774671
SNP was associated with rs1131454 (former rs3741981)
as a haplotype in Type 1 diabetics. The rs1131454 SNP
(former rs3741981) is an A or G positioned in exon 3
resulting in an OAS1 protein with either Ser162 or
Gly162 in the core domain. The association between these
two SNPs and Type 1 diabetes has not been confirmed in
a larger study, though others have concluded that there
may be a very weak association between the rs1131454
(former rs3741981) and rs10774671 SNPs and Type 1
diabetes in a population of European descents, however
these authors stated that this association might also be
linked to other SNPs in the OAS1 locus [16,17]. In
multiple sclerosis the same haplotype was studied in a
Spanish study group [18]. They found that the G allele
of rs10774671 and the A allele of rs1131454 (former
rs3741981) seemed to increase the risk of having mul-
tiple sclerosis, which is the same risk haplotype seen
for Type 1 diabetes. In an Irish study, only considering
the rs10774671 SNP, the opposite was found, in that
the G allele showed to be protective of multiple sclerosis
whereas the A allele conferred susceptibility [19]. The AA
genotype was associated with disease activity despite IFNβ
therapy and earlier breakthrough of multiple sclerosis
upon IFNβ therapy, whereas the GG genotype was associ-
ated with delayed breakthrough relapses upon IFNβ
therapy. Finally, in an Italian study no association wasfound between rs10774671 and multiple sclerosis [20].
Thus the association with the two OAS1 SNPs,
rs10774671 and rs1131454 (former rs3741981), and
type 1 diabetes or multiple sclerosis remain elusive.
An association was found with the OAS1 SNP
rs10774671 and the response to measles vaccination in
an African-American population [21]. The A allele was
associated with higher levels of measles neutralizing
antibodies in a dose dependent manner with regard to
the genotype AA >AG>GG. During rubella vaccinations,
the A allele was associated with lower rubella virus
specific IL-2 secretion and the G allele with higher IL-2
secretion [22]. It seems as if OAS1 gene polymorphism
might also be involved in the mechanism underlying
the heterogeneous immune response to rubella and mea-
sles vaccinations.
During West Nile Virus (WNV) infections, the AA
genotype of rs10774671 resulted in higher virus titers
than AG or GG genotypes when tested in an ex vivo
model of WNV replication in cultured human lymphoid
tissue [23]. It was concluded that the rs10774671 is a host
genetic risk factor for initial WNV infection in humans.
However, this specific association could not be seen in a
more recent case-control study, although an association
was seen between the SNP rs34137742 positioned in the
intron between exon 2 and exon 3 in the OAS1 gene and
an increased risk for WNV encephalitis and paralysis [24].
In Hepatitis C virus (HCV) patients it was found that
patients with AA in rs10774671 were non-responders
to interferon treatment and they had a progressive
HCV disease [25]. When overexpressing the individual
OAS proteins in human hepatoma Huh7 cells, OAS1 p46
as well as OAS3 p100 could inhibit HCV replication,
whereas the OAS1 isoforms p42, p48 and p52 and the
OAS2 isoforms p69 and p71 could not [26]. This suggests
that expression of p46 caused by the G allele of the
rs10774671 SNP is protective of HCV infection, or the A
allele could be a risk factor. Overexpression of individual
OAS proteins in A549 cells infected with Dengue virus
resulted in antiviral effects of the OAS1 p42 and p46 and
the OAS3 p100 [27]. The other OAS proteins, OAS1
p44b, p48 and p52 as well as the OAS2 p69 and p71 did
not lead to antiviral effects. This suggests that the A allele
of the rs10774671 SNP could be a risk factor for Dengue
infection. In conclusion, infection of the flaviviruses WNV,
Dengue virus and HCV seem to be inhibited by expression
of the p46 OAS1 protein derived from the presence of the
G allele of the rs10774671 SNP in the OAS1 gene.
Total OAS enzyme activity analysis of peripheral blood
lymphocytes from 147 individuals revealed that persons
with the A allele in rs10774671 had a lower total OAS
enzymatic activity compared with persons with the G
allele [9]. The OAS activity decreased in a dose dependent
manner, the genotype GG >GA>AA. This could be due
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encoded by the A allele, p46 encoded by the G allele, or
differential levels of p48 encoded by either allele. No
evidence has yet been presented to support this, as the
levels of p46, p48 and p52 OAS1 proteins in these cells
were not analysed. The difference in total OAS activity
in the leukocytes observed could also be a result of other
SNPs in the OAS locus, which could be linked as haplo-
types to the A and G alleles of the SNP rs10774671.
In order to clarify some of the consequences of two of
the important SNPs (rs10774671 and rs1131454 (former
rs3741981)) in the OAS1 gene, we have determined the
mRNA expression profiles of the OAS1, OAS2 and OAS3
genes in three different cell lines with different OAS1
genotypes at the rs10774671 position. Furthermore, we
have analysed the OAS protein expression patterns of
these three cell lines and determined the total OAS
enzyme activity after interferon treatment. We have
determined the functional effects of rs1131454 (former
rs3741981), which results in two isoforms of the OAS1
proteins by analysing two mutants of an OAS1 core
protein, one containing a Serine and the other a Glycine
at position 162 in the primary structure. Finally, we
present evidence of the specific cellular localization of the
OAS1 isoform p46 to the mitochondria, which differs
from p42.
Results
In order to address potential influences of the rs10774671
polymorphism (Figure 1) on the OAS1 gene expression
and enzyme activities relating to the A and G alleles, we
set out to identify the OAS mRNA expression profiles and
the OAS enzyme activities in three human cell lines,
distinguished by their OAS1 GG, GA and AA genotypes.
Through DNA sequencing of genomic DNA retrieved
from the three cell lines we found that HeLa cells are
homozygous for the A allele (AA), HT1080 cells are
heterozygous (AG) and Daudi cells are homozygous for
the G allele (GG) with respect to the rs10774671
polymorphism.
mRNA expression profiles of the OAS splice variants
In order to create a full expression profile of the OAS1
splice variants p42, p44a, p44b, p46, p48 and p52, we
carried out qRT-PCR analyses to measure the mRNA
levels of the different isoforms. Primers were created
with a forward primer annealing within the exon 1-5
core region whereas a downstream reverse primer was
designed to specifically amplify each splice variant
(Figure 1A and Table 1). The p46 and p52 mRNAs could
not be distinguished in this qRT-PCR due to only a
single nucleotide difference, and several attempts to
produce a usable reverse primer failed. We therefore
made the assumption that HeLa cells do not express p46and Daudi cells not p52, as a consequence of the AA/
GG genotypes of these cell lines with respect to the
rs10774671 polymorphism. HeLa, HT1080 and Daudi
cells were treated with IFN-β, or left un-treated as con-
trols for 24 hours. Total RNA was isolated and qRT-PCR
analyses were performed using GAPDH for normalization,
which did not change during the experimental set-up. The
main OAS1 mRNA product found in HeLa cells treated
with IFN was the unspliced p42 isoform, with a smaller
amount of spliced p52 mRNA and only trace amounts of
p48 mRNA detected (Figure 2A). In the heterozygous cell
line HT1080 treated with IFN, there was predominantly
the spliced p46/52 mRNAs and less of the p42 mRNA.
The main OAS1 mRNA in Daudi cells was the spliced
p46, and this mRNA was present in control cells at a con-
siderable amount, and the level increased after interferon
treatment. Of the other OAS1 isoforms only very low-
inducible amounts of p44a and p48 mRNAs could be
detected in the three cell lines and we were unable to
detect p44b mRNA in any of the cell lines. All qRT-PCR
dissociation curves indicated single PCR products. This
was confirmed by agarose gel electrophoresis of all the
qRT-PCR samples, revealing the amplification of the ex-
pected band size for each OAS1 mRNA (data not shown).
We then determined mRNA expression profiles of the
OAS2 (p69 and p71) and OAS3 mRNAs (p100) in the
three cell lines (Figure 2B). The OAS2 p69 and p71
mRNAs were found to increase after interferon treat-
ment in the three cell lines, whereas the OAS3 p100
mRNA was induced in HeLa and HT1080 cells and was
barely detectable in Daudi cells. Daudi and HT1080 cells
primarily expressed the OAS2 p69 mRNA, whereas
HeLa cells expressed both the p71 and p69 mRNAs.
Daudi cells also expressed p69 mRNA in untreated cells.
Protein expression profiles of the OAS isoforms and total
OAS enzyme activity
We then carried out immunoblotting analysis of protein
extracts from the three cell lines using different anti-
OAS antibodies in order to compare the protein levels
(Figure 3). Initially, the OAS1 isoforms were analysed by
an anti-OAS1 antibody targeting all OAS1 variants, and
the ability of the anti-OAS1 antibody to recognize all the
OAS1 isoforms was verified by expression of the individual
OAS1 isoforms in HeLa cells after transient transfection
(Figure 3A). In the cell lines HeLa, HT1080 and Daudi,
only the OAS1 isoforms p42 and p46 could be detected
(Figure 3B). An IFN-α and IFN-β inducible expression of
p42 was seen in HeLa cells, whereas Daudi cells had an
IFN-α and IFN-β inducible expression of p46. Daudi cells
expressed the p46 protein constitutively, whereas p42
could only be detected after IFN-α and IFN-β treatment of
the HeLa cells. In the heterozygous HT1080 cells, the rela-
tive levels of expressed protein, i.e. p42 or p46 following
Table 1 Primers for quantitative reverse transcriptase PCR
Target mRNA Forward primer Reverse primer
OAS1 p42 5'-GGTCTTGGAATTAGTCATAAACTACCA-3' 5'-ATGAATGGCAGGGAGGAAG-3'
OAS1 p42/p46 5'-GAGAAGGCAGCTCACGAAAC-3' 5'-CGTCTGCACTGTTGCTTTCAGCC-3'
OAS1 p48 5'-GGTCTTGGAATTAGTCATAAACTACCA-3' 5'-GAGTGTGCTGGGTCAGCAGAATCCAG-3'
OAS1 p44a 5'-GGTCTTGGAATTAGTCATAAACTACCA-3' 5'-AGTGACATGAGCACTGGCTTT-3'
GAPDH 5'-GGTCGGAGTCAACGGATTT-3' 5'-CCAGCATCGCCCCACTTG-3'
OAS2 p69 5'-GGAAGTTTCTACTGAGCCAGTTGCAG-3' 5'-GACAACGCCTCCTTTAGATGAC-3'
OAS2 p71 5'-GGAAGTTTCTACTGAGCCAGTTGCAG-3' 5'-GGTGTCTGCATTGTCGGCACTTTCCAAG-3'
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Figure 2 OAS mRNA expression profiles. qRT-PCR analyses of the indicated (A) OAS1 mRNAs and (B) OAS2 and OAS3 mRNAs before (-) and
after treatment with IFN-β (+) in HeLa cells (AA genotype), HT1080 cells (AG genotype), and Daudi cells (GG genotype). The mRNA levels were
normalized to GAPDH mRNA levels. The experiments were done in triplicates. Error bars are SEM in (A), and SD in (B).
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Figure 3 (See legend on next page.)
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Figure 3 Cell line-specific OAS protein expression and enzyme activity. A. HeLa cells were transfected with plasmid constructs encoding
the indicated OAS1 variants or the empty control vector. Cells were harvested and lysed at the indicated time after transfection and subjected to
immunoblot analysis using the OAS1 specific antibody. The positions of the recombinantly expressed OAS1 isoforms are indicated. The position
of the endogenously expressed p42 is indicated by an arrow-head. B. Immunoblot analysis of human OAS proteins in HeLa (AA genotype),
HT1080 (AG genotype), and Daudi (GG genotype) cells. Cells were either treated with IFN-α, -β and –γ or left untreated (-) for 24 hours, as
indicated. The OAS1 proteins were detected by the monoclonal anti-OAS1 antibody, and the OAS2 and the OAS3 proteins with anti-OAS2 and
anti-OAS3 antibodies, respectively. C: Protein extracts from HeLa cells transfected with constructs expressing either p46 or p69. α-tubulin was
employed as loading control. Unspecific bands recognized by the antibodies are indicated by *. C. Total OAS enzyme activity of HeLa, HT1080
and Daudi cell lysates treated with IFN-β (+) or left untreated (-). Enzyme activities were determined using ATP as substrate. The reaction products
were visualized by Mono Q chromatography. Peaks were integrated and used to calculate the specific enzyme activities using the total protein
concentration in each cell lysate. Results are an average of three independent experiments. Error bars represent SD.
ns
Figure 4 Specific enzyme activity of p39G and p39S truncated
OAS1 variants. The indicated proteins were purified after expression
in E.coli. Purified proteins were analysed for OAS activity with ATP as
substrate. The reaction products were visualized by Mono Q
chromatography. Peaks were integrated and used to calculate specific
enzyme activities. Results are an average of three independent assays.
Error bars represent SEM.
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form with the level of p42 being very low. No other OAS1
isoforms were detected in the immunoblotting analysis,
most likely due to low levels of protein expression, and
the protein expression pattern was found to correlate
with the qRT-PCR analyses. We would have expected
an expression of p52 in HT1080 and HeLa cells due to
the presence of the A allele of the rs10774671 in these
cell lines, however the p42 isoform mRNA unspliced
between exon 5 and exon 7 prevailed in HeLa cells, and
the allele expressing the spliced p46 isoform prevailed
in the HT1080 cells.
Although a recombinantly expressed OAS2 p69 iso-
form could be detected in transfected HeLa cells, none
of the OAS2 isoforms were detected in the cell lines,
even though their mRNAs were present in high amounts
(Figure 3B). We tried several commercially available OAS2
antibodies, however none of these detected endogenous
expression of the OAS2 proteins. When using an OAS
specific peptide antibody recognizing all OAS isoforms, we
observed that the OAS2 proteins were indeed expressed in
these cell lines in accordance with the OAS2 mRNA levels
(data not shown). And finally, the OAS3 isoform p100 was
expressed in IFN-α and IFN-β treated HeLa and HT1080
cells, but not in Daudi cells, also in accordance with the
mRNA levels. None of the OAS isoforms were induced by
IFN-γ in any of the three cell lines.
Total OAS enzyme activity assays were carried out on
crude cell extracts from the three cell lines, untreated
and treated with IFNβ (Figure 3C). We found that HeLa
and HT1080 cells had equal inducible OAS enzyme
activities. This OAS activity originated from the OAS1
isoforms p42 in HeLa and mainly p46 in HT1080,
together with the OAS2 isoforms p69 and p71, and the
OAS3 isoform p100. Daudi cells had a high constitutive
OAS activity, which could be increased by IFNβ treat-
ment. The OAS enzyme activity in Daudi cells originated
from the OAS1 p46 isoform and the OAS2 p69 and p71
isoforms. The constitutive expression of OAS1 and OAS2
in the Daudi cell line could be due to it originating from a
B lymphoblast, since B-cell lymphocytes are known to
constitutively express various cytokines [28].Enzyme activities of OAS1 mutants associated with the
rs1131454 (former rs3741981) polymorphism
We next wanted to analyse if the SNP rs1131454 (former
rs3741981) (Gly or Ser at position 162 in OAS1) influ-
ences the OAS1 enzymatic activity considering its position
in the OAS1 core unit. Thus we measured the specific
OAS enzyme activities of two truncated OAS1 proteins
i.e. p39G/p39S distinguished by only a single amino
acid mutation (Gly/Ser) at position 162 giving rise to
proteins of ~39 kDa (p39). The specific activities of the
p39G and p39S variants were found not to differ (Figure 4).
We therefore concluded that the specific activity of the
OAS1 isoforms with Gly162 or Ser162 deriving from the
rs1131454 (former rs3741981) SNP have indistinguishable
specific enzyme activities.
Cellular localization of the OAS1 p46 and p42 isoforms
Previous analyses of the localization of the OAS1 iso-
forms have been conducted using either highly expressed
recombinant proteins or using antibodies recognizing all
OAS isoforms. Using HeLa and Daudi cells expressing
mainly p42 or p46 combined with the very specific
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localization of these two OAS1 isoforms.
HeLa and Daudi cells were stimulated with IFN-β for
24 hours and fixed cells were then subjected to immuno-
fluorescence cytochemistry and electron microscopy
using the anti-OAS1 antibody (Figure 5). The fixed cell
pellets were cryosectioned, and this allow for analyses of
endogenous proteins without prior permeabilisation and a
good resolution of the immunofluoresence cytochemistry.
As a mitochondrial tracker in these immunofluoresence
analyses, we used an antibody against the mitochondrial
protein VDAC1. The results obtained from Daudi cells
showed that the OAS1 p46 isoform, which is the main
OAS1 isoform present in these cells together with very
low amounts of p48 detected on the mRNA level
(Figure 5A, green), co-localized with the mitochondrial
protein (red), and this was clearly seen in the merged
picture (yellow). The localisation of p46 to the mito-
chondria was also supported by electron microscopy
(Figure 5A, bottom images), showing concentrated
staining of p46 in the mitochondria. The cellular local-
ization of the OAS1 isoforms in HeLa cells is different.
The OAS1 isoforms distributed throughout the cytoplasm
(Figure 5B, green), which does not perfectly co-localize
with the VDAC1 mitochondrial protein (Figure 5B, red),
seen in the merged picture as yellow stain. This finding is
supported by the electron microscopy, showing that the
HeLa OAS1 isoforms associated with organelle structures
resembling vacuoles/lysosomes in the cytoplasm as well
as with the mitochondria (Figure 5B, bottom images).
The main OAS1 isoform present in HeLa cells was p42
together with low amounts of p52 detected on the
mRNA level.
In order to establish if the mitochondrial localization of
p46 was cell type specific for Daudi cells, we overexpressed
OAS1 p46 and p42 in HeLa cells after transient transfec-
tions (Figure 6). Also in HeLa cells, p46 is localised to the
mitochondria seen as a co-localization with the Mito-
tracker. Overexpressed p42 distributed evenly in the HeLa
cells, as we have seen previously with overexpressed
His-tagged OAS1 p42 protein [29]. Since the trans-
fected HeLa cells were not treated with interferon, no
endogenous OAS1 proteins could be detected in the
un-transfected cells.
We therefore concluded that the OAS1 p46 isoform
localized in the mitochondria, whereas the OAS1 p42
isoform mainly localized in vacuoles/lysosomes within
the cytoplasm as well as in the mitochondria.
Discussion
Several theories have been proposed regarding the associ-
ation of SNPs in the OAS1 gene with different diseases,
but no direct correlation between the SNPs and the
expression pattern and specific enzymatic activities hasbeen shown up till now. The OAS1 mRNAs can be dif-
ferentially spliced according to a polymorphism at the
splice acceptor site of exon 7 (rs10774671), and it has
been observed that lymphocytes from individuals with
the G allele have a higher total OAS enzymatic activity
than individuals with the A allele [9].
Bonnevie-Nielsen et al. [9] showed in leukocytes that
the A and G alleles of the rs10774671 SNP could be
associated with the presence of either the p48 and p52
or the p46 OAS1 mRNAs, respectively. However, the in-
dividual levels of OAS1 proteins were not investigated,
and the level of p42 mRNA unspliced between exon 5 and
exon 7 was not analysed either. We have now demon-
strated that the A allele present in HeLa cells primarily
leads to expression of the unspliced p42 mRNA and only
secondary to the spliced p52 mRNA, whereas the G allele
present in Daudi cells leads to expression of the spliced
p46 mRNA and to a lower extent of p48 mRNA. Only the
p42 and p46 isoforms could be detected by immunoblot-
ting analyses, whereas p44a, p48 and p52 mRNAs were
only detected by qRT-PCR. The finding of p42 and p46 as
the main OAS1 proteins expressed is also supported by
earlier immunoblotting analyses [30].
Very recently, the rs10774671 polymorphism was ana-
lysed in human bronchial epithelial cells [10]. In bron-
chial cells with the GG genotype only the p46 isoform
was detected, whereas in the cells with the AA genotype
the expression of the unspliced p42 isoform prevailed
the expression of the spliced isoforms p44a, p48, and
p52, as the latter three were only detected at the mRNA
level. Also in HT1080 cells, previous results showed that
the endogenous level of the OAS1 p48 isoform was very
low [8]. Accordingly, the A allele most likely prompts
primarily to the production of the unspliced p42 isoform,
and the G allele the production of the spliced p46 isoform.
However, it can not be excluded that p48 and p52 might
be expressed at higher levels in leukocytes harbouring
the A allele together with p42, since splicing is cell
type-specific.
Although debated, it has been suggested that the
SNPs rs10774671 and rs1131454 (former rs3741981)
may be linked as a haplotype [15]. We have analysed the
functional effect of the rs1131454 (former rs3741981)
SNP, and found that the p39G truncated OAS1 variant
exhibited the same specific OAS enzyme activity as the
p39S variant. Consequently, the increased OAS enzyme
activities in leukocytes with the G allele is unlikely to
be caused by a higher specific enzyme activity of
Gly162 containing OAS1 variants compared with the
Ser162 containing OAS1 variants. The contribution of
the the OAS2 and OAS3 proteins to the total OAS
activity in the three cell lines investigated here is not

















Figure 5 Cellular localization of endogenous OAS1 p42 in HeLa and p46 in Daudi cells. (A) Daudi cells and (B) HeLa cells were treated
with IFN-β for 24 hours. The cells were fixed and prepared for immunofluorescence microscopy (upper panels), which was carried out with the
anti-OAS1 antibody and a FITC-conjugated secondary antibody (green). p46 OAS1 was detected in Daudi cells and mainly p42 OAS1 in HeLa cells.
Red fluorescence shows the localization of the mitochondrial specific protein VDAC1. Yellow fluorescence indicates the degree of co-localization
between the OAS1 proteins and the mitochondrial protein in the merged pictures. Electron microscopy (lower panels) shows localization of the
p46 OAS1 protein in Daudi cells and mainly p42 in HeLa cells. Gold particle labeling demonstrates the localization of the OAS1 proteins. Black
arrows indicate OAS1 proteins in the mitochondria and red arrows OAS1 proteins in vacuoles/lysosomes in the cytoplasm. The white bars are
10 μm and the black bars 0.5 μm. N: the nucleus. G: Golgi apparatus.
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OAS1 Mitotracker DAPI Merge
p42
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Figure 6 Cellular localization of overexpressed OAS1 p42 and p46 isoforms in HeLa cells. HeLa cells were transfected with plasmids encoding
OAS1 p42 or p46, as indicated. Prior to fixation the cells were treated with Mitotracker (red). The cells were incubated with the OAS1 primary antibody
and a FITC-conjugated secondary antibody (green). The nuclei were stained with DAPI (blue). Yellow fluorescence indicates the degree of co-localization
between the OAS1 p42 or p46 proteins and the mitotracker in the merged pictures. The frame in the merged picture indicates the magnified area.
Arrows indicate some of the positions of co-localization. The white bars are 10 μm.
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isoforms in HeLa and Daudi cells harbour a differential
cellular localization. The main OAS1 isoform p46 ex-
pressed in Daudi cells was found to be localized in the
mitochondria and no OAS1 was found in the cytoplasm.
In HeLa cells, the main OAS1 isoform p42 was localized
in cytosolic compartments resembling vacuoles/lyso-
somes as well as in the mitochondria. When the OAS1
p46 isoform was overexpressed in HeLa cells, it also
localized in the mitochondria ruling out the possibility
of a cell type specific localization of p46 in Daudi cells.
This supports earlier findings that p42 and p46 are in
the cytoplasmic as well as in microsomal fractions, p42
mostly in the cytoplasm and p46 mainly in association
with the microsomal fraction [6], which probably con-
tained the mitochondria.
The expression of the OAS1 isoform p46 encoded by
the presence of the G allele leads to: (1) High OAS
enzyme activity in leukocytes from Type 1 diabetics, (2)
Low response to measles vaccination and higher virus-
specific IL-2 secretion during rubella vaccination, and (3)
Inhibition of WNV, HCV and Dengue virus replication.
Additionally it has been documented that the G allele
hence p46 seems to predominate in skin fibroblasts
derived from Alzheimer disease patients [31]. The dif-
ference in cellular localization between the p42 and p46
isoforms identified here could potentially explain part
of these associations. The presence of p46 in the mito-
chondria may lead to longer half-life of the protein, and
thus sustained OAS activity in the cells. The shift in OAS
enzyme activities towards mitochondria may improve
conditions for apoptosis, since mitochondria is a key
player in the intrinsic apoptotic pathway [32]. Both of
these hypotheses are speculative at the moment.
Although our goal was to unravel the putative function-
ality of the rs10774671 and rs1131454 (former rs3741981)
OAS1 SNPs, the identification of the p46 OAS1 isoform
in mitochondria adds to the understanding of the 2-5Asystem. We have previously found a conserved CaaX motif
in a number of OAS1 isoforms [33], which are conserved
in several species [34]. The CaaX motif is known to be
important for geranylation or farnesylation of protein
targets, and is believed to functionally direct these to
cellular membranes. We therefore suggest that the local-
ization of the different OAS1 isoforms could differ depend-
ing on the presence of this CaaX motif in the C-terminus.
In humans, only the p46 isoform holds this C-terminal
CaaX motif, while the other OAS1 isoforms including
p42 do not. Further experiments are required to investi-
gate this hypothesis.
We have previously shown that the 2′-phosphodiesterase
PDE12, a nuclease degrading 2-5As is also localized to the
mitochondria or more specifically to the mitochondrial
matrix [29]. This mitochondrial localization was found
puzzling with regard to the 2-5A system, since no OAS
enzymes at that time had been found in mitochondria.
Accordingly, if most 2-5As were produced and active in
the cytoplasmic compartment, the mitochondrial inner
membrane would logically pose a hydrophobic barrier
hindering the PDE12 from accessing its 2-5A substrates.
Previously, an activated RNase L was also found in the
mitochondria although a broad cellular distribution was
observed for this enzyme [35-37]. It is therefore now pos-
sible to put forward a model with a complete 2-5A system
in the mitochondria (Figure 7). Since the PDE12 share
similarities with other RNA deadenylases and was found
to degrade 3′-5′ RNA linkages also, it was suggested that
it had a role in mitochondrial RNA turnover. Our results
and results from others indicated that the PDE12 was
indeed regulating mitochondrial mRNAs [29,38]. In
addition, it has also been suggested that mitochondrial
RNase L might influence mitochondrial mRNA turn-
over and induce apoptosis, when cells are stimulated by
IFNα [39]. If this is the case, the p46 isoform might
contribute to the regulation of mitochondrial RNA turn-
over as an activator of RNase L. Hence, the p46 isoform
Figure 7 Model of the 2-5A system. OAS and RNase L, two of the
enzymes constituting the 2-5A system, localizes to the cytoplasm as well
as to the mitochondria rendering a full 2-5A system present in both the
cytoplasm and the mitochondria (light green/ivory). Individuals carrying
the G allele of polymorphism rs10774671 generally have a higher
amount of OAS protein in the mitochondria represented by the OAS1
p46 isoform (red arrows), whereas individuals harbouring the A allele in
general have higher levels of OAS in the cytoplasm (black arrows). The
2-5As synthesized in the cytoplasm, activate cytosolic RNaseL and are
themselves regulated by an unknown 5′-phosphatase. The resulting
products, 2-5A core molecules are transported to the mitochondrial
matrix and degraded by a 2′ phosphodiesterase (known as PDE12), or
alternatively, degraded by an unknown 2′phosphodiesterase located in
the cytosol. 2-5As are also synthesized in the mitochondria leading to
activation of mitochondrial RNaseL. The 2-5As are here prone to direct
degradation by PDE12, or alternatively trimmed by a phosphatase before
degradation by PDE12. The cell is not drawn to scale.
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RNase L in mitochondria.
Conclusions
We have found that the SNP rs10774671 in the OAS1
gene mainly leads to expression of either the p46 isoform
or the p42 isoform. In the SNP associated with diabetes,
the expression of the OAS1 isoform p46 prevails, and we
have seen that this isoform is localized to the mitochon-
dria. Our data support a model that in certain conditions
the mitochondria can harbour a full 2-5A system, which
might contribute to interferon stimulated apoptosis.
Methods
Cell lines
HeLa (ATTC: CCL-2) and HT1080 (ATCC: CCL-121)
cells were cultured as adherent cells at 37°C with 5%
CO2 in Dulbecco’s modified Eagle’s medium containing
10% fetal bovine serum and 1% Penicillin/Streptomycin.
Daudi cells (ATCC: CCL-213) were cultured as suspen-
sion cultures using similar conditions in Roswell ParkMemorial Institute medium with 5% fetal bovine serum
and 1% Penicillin/Streptomycin. The cells were grown to
80% confluence or 106 cells/ml and treated with 500
units/mL of IFN-α, 500 units/mL of IFN-β, 100 units/
mL of IFN-γ or left untreated as controls for 40 hours.
Adherent cells were harvested with a cell scraper, pel-
leted at 230 ×g for 10 minutes at 4°C and washed once
in PBS. The Daudi cells were harvested by centrifugation
and washed once. Transfections of HeLa cells with
either OAS1 cDNAs or OAS2 p69 cDNA under the
control of the CMV promotor and control plasmids
were performed with either TurboFect Transfection
Reagent (Fermentas) following the manufactures proto-
col or using the polyethylenimine (PEI) method [40] for
the immunofluoresence cytochemistry studies. In brief,
linear PEI (25,000 Da) was used and complexes of DNA:
PEI at ratios 1:8 (w/w) were allowed to form and added to
the cells. Cells were incubated for 24-25 hours after trans-
fection, and during this time the growth medium was chan-
ged five hours after addition of the DNA:PEI complexes.
Purification and sequencing of genomic DNA
Untreated cell pellets were washed once in nuclei lysis
buffer (0.1 M Tris EDTA, pH 8.0; 0.4 M NaCl; 2 mM
EDTA). The pellets were then resuspended in the same
nuclei lysis buffer, pre-added 2 mg/ml Proteinase K and
8% SDS, and incubated over night at 45°C. The cell
lysates were added NaCl to a final concentration of 4 M,
and the tubes vortexed for 15 sec. Samples were then
centrifuged at 845 ×g for 15 min. The supernatants were
centrifuged repeatedly until samples were clear of salt, at
least 3 times. Cleared supernatants were then added 1/
10 volume of 3 M sodium acetate (pH 5.2) and 3 volumes
of cold isopropanol and gently shaken. The precipitated
DNA was resuspended in 70% ethanol, and tubes were
placed on inverting racks for 2 hours. The DNA threads
were then isolated and centrifuged for 30 minutes at
18,400 ×g. DNA pellets were dried, and resuspended in
ddH20, left at 37°C overnight, and stored at -20°C. The
DNA of interest covering the rs10774671 SNP was PCR
amplified using the primers; Fw: 5′-GCTAACAAGTG
GTGGAAA-3′, Rv: 5′-AAATGAAGGAACTGGTCC-
3′, and the amplified product gel-extracted with the
DNA and gel band purification kit (GE Healthcare). DNA
sequencing was performed with the BigDye Terminator
Kit (Applied Biosystems) using the same primers as in the
amplification reaction.
mRNA purification and first strand synthesis
Total mRNA was purified using the QuickPrep Micro
mRNA purification kit from Pharmacia. cDNAs were
synthesized using the SuperScriptTMII Reverse Tran-
scriptase kit (Invitrogen) with 100 ng of mRNA and 2
pmol of Oligo(dT)18 primer.
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Quantitative reverse transcriptase (qRT)-PCR reactions
were carried out using the SYBR Green qPCR Supermix
universal kit (Invitrogen) on a Stratagene Mx3005p. The
utilized primers are listed in Table 1. The reaction
conditions were optimized with regard to annealing
temperature and primer concentration, and the reaction
mixes were as follows: 1 × Platinum SYBR Green qPCR
SuperMix-UDG (Invitrogen), 0.2% ROX Reference Dye,
250 nM of each primer and 1 μl of template cDNA in
total volumes of 20 μl. The results were obtained with
the Mx3005P System (Stratagene), running a thermal
program of 95°C for 10 min and then 40 cycles of [95°C
for 10 s; 55°C for 20 s (at the end of which the SYBR
green fluorescence was measured); and 72°C for 20 s].
After this, the samples were heated to 95°C for 1 min and
lastly cooled to 55°C, and dissociation curves were ob-
tained by measuring the decay of SYBR green fluorescence
when heating the samples from 55 to 95°C. Accurate PCR
product band sizes were verified by standard agarose gel
electrophoresis, and melting curve analysis of all four PCR
products displayed single melting peaks. DNA fragments
were in turn excised from the gel, purified as described
above and identified by sequencing. All obtained signal
levels were normalized to the ROX reference dye levels
for correction of errors due to differences in plastic ware
transparency and reflectivity or aliquoting errors. Overall
threshold fluorescence levels were determined with the
default adaptive baseline method of the MxPro Software,
and the resulting Ct values were converted to quantities
using the comparative Ct method. This calculation incor-
porated the efficiencies of the reaction with each primer
set, which were determined. Efficiency was measured
using a standard curve generated by serial dilutions of the
cDNA. The PCR efficiency (E) was calculated by the for-
mula: E = 10 (1/-slope) - 1, and ranged from 90–110% in
the different assays (a slope of -3.32 is equivalent to 100%
PCR efficiency) [41]. Finally, each result was normalized
to the GAPDH housekeeping gene, which did not change
levels during the experiment.
Immunoblotting analysis
Cells treated with interferons or left untreated as controls
were lysed in Radioimmunoprecipitation assay buffer
(150 mM NaCl, 10 mM Tris, pH 7.2, 0.1% SDS, 1% Triton
X-100, 1% Deoxycholate, 5 mM EDTA). Equal amounts of
total protein extracts were subjected to 10% SDS-PAGE
and transferred to PVDF membranes. Proteins were
detected using the following antibodies: A mouse mono-
clonal human anti-OAS1 antibody (a kind gift from
Illumigen Bioscience Inc., Seattle, USA), a rabbit peptide
OAS antibody (raised against the peptide B as described
[6], a kind gift from professor Vagn Bonnevie-Nielsen,
Vancouver, Canada), anti-OAS2 (abcam), anti-OAS3(C-15, Santa Cruz), and anti-α-tubulin (Sigma) together
with appropriate HRP-conjugated secondary antibodies
(donkey anti-goat, Santa Cruz; goat anti-mouse, GE
Healthcare; goat anti-rabbit, Dako Denmark). Proteins
were visualized using the ECL plus chemiluminescence
reagent (GE Healthcare).
OAS enzyme activity assay
Cells treated with IFN-β and untreated controls were
lysed in lysis buffer E (0.5 M CH3COOK, 1% NP-40,
20 mM Tris-HCl, pH 7.8, 1 mM DTT, 0.2 mM EDTA,
5 mM Mg(OAc)2 and 10% glycerol). Total protein con-
centrations were measured with the BCA kit (Pierce).
Total OAS activity was measured as described in [29,42]
using protein extracts in a total volume of 200 μL with
0.1 mg/ml of Creatine Kinase and 6 mM of Creatine
Phosphate.
Specific OAS enzyme activities were determined using
165 ng of the purified His Tagged proteins p39G and
p39S (kind gifts from Illumigen Bioscience Inc., Seattle,
USA) in the assays. The proteins are human truncated
OAS1 isoforms, obtained by recombinant expression in
E. coli followed by a two-step purification using Ni-NTA
and gel filtration chromatography. The p39G and p39S are
truncated isoforms of OAS1 p42 (Accession nr. 1207325A)
containing only the first 355 amino acid residues with
either a Gly or a Ser at amino acid residue position 162.
Immunofluorescence cytochemistry and electron
microscopy
Interferon treated Daudi and HeLa cells were fixed at
room temperature in 0.01 M phosphate-buffered saline
(PBS), pH 7.4 with 4% formaldehyde for 30 min for immu-
nofluorescence cytochemistry or 2% formaldehyde and
0.1% glutaraldehyde for 10 min for electron microscopy.
The cells were washed three times and removed from the
support with a rubber policeman in the same buffer,
containing 1% gelatine (Merck), pelleted and embedded in
12% gelatine, and finally infiltrated with 2.3 M sucrose in
PBS for 30 min, and frozen in liquid nitrogen. For light
microscopy, semithin (0.8 μm) cryosections were sectioned
at -80°C on a FCS Reichert Ultracut S cryoultramicrotome
and preincubated with 0.01 M PBS, 1% BSA or 0.1% milk,
0.05 M glycine, pH 7.4, followed by incubation with
primary antibodies (mouse anti-OAS1,1:100 and rabbit
anti-VDAC1, 1:10 (Abcam)) for one hour and subsequently
by fluorescence conjugated secondary antibodies for one
hour at room temperature. The sections were examined in
a Zeiss Axioplan fluorescence microscope.
Ultrathin cryosections (70 - 90 nm) were obtained at
about -100°C and collected on 200 mesh Ni grids. The
sections were incubated overnight with a mouse anti-OAS1
antibody 1:100 prior to 2 h incubation with goat anti-
mouse gold (10 nm) (BioCell, Cardiff, UK). All incubations
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with methyl cellulose containing 0.3% uranylacetate and
studied in a FEI CM100 electron microscope.
For overexpression of OAS1 p42 and p46, HeLa cells
were seeded on coverslips and transfected with plasmids
encoding p42, p46 or control plasmids using the PEI
method (see above). After 24-25 hours, 100 nM of Mito-
tracker Red CMXRos (Molecular Probes, Invitrogen)
was added to the cells for 25 minutes. Cells were then
fixed with 4% paraformaldehyde, washed in PBS, perme-
abilized with 0.05% Triton X-100 for 10 minutes, washed
twice with PBS and finally blocked with 3% BSA in PBS-
Tween. The cells were then incubated with the mouse
anti-OAS1 antibody (1:200) followed by incubation with
a FITC-conjugated anti-mouse antibody (1:250, Sigma).
The coverslips were mounted with ProLong Gold with
DAPI (Molecular Probes, Invitrogen) for visualization of
the nuclei. Regular wide field epifluorescence microscopy
was performed on a Zeiss Axiovert 200 M Inverted Fluor-
escence Microscope equipped with a 63× oil-immersion
lens (NA 1.4) and an HBO lamp. Images were collected
with a Photometric CoolSnapTM HQ camera from Roper
Scientific controlled by MetaMorph acquisition software.
The images were analysed with ImageJ [43] and Photoshop.
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